RxDoctor Payments Data

Anna Virin

Nurse Practitioner · Roseville, CANPI 1639642465

Payments from drug & device makers

$1,954in general payments, 2019–2025

Across 69 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$511
  • AbbVie$427
  • Otsuka America Pharmaceutical, Inc.$320
  • Takeda Pharmaceuticals U.S.A., Inc.$248
  • Bausch Health US, LLC$133
  • Johnson & Johnson$115
  • plus $199 from 4 others

What the payments were for

  • Food & beverage$1,90798%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,954 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$53,557
Medicare patients
79
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl13$11,356
Aripiprazole86$7,070
VyvanseLisdexamfetamine Dimesylate12$4,382
InvegaPaliperidone12$3,942
Divalproex Sodium ErDivalproex Sodium66$3,727
Bupropion XlBupropion Hcl65$2,973
Atomoxetine Hcl20$2,725
Ramelteon15$1,966
Quetiapine Fumarate72$1,847
Methylphenidate ErMethylphenidate Hcl12$1,757
Sertraline Hcl92$1,262
Mirtazapine78$1,175
Duloxetine Hcl51$650
Trazodone Hcl70$611
Olanzapine16$567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$248$4,38212 claims
Johnson & JohnsonInvega$115$3,94212 claims
Almatica Pharma LLCSertraline Hcl$21$1,26292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →